Xencor, Inc. (NASDAQ: XNCR) announced that Phase 1 study results of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA